Novavax has started sharing early clinical data for its COVID-19 vaccine with health authorities in the UK, EU, US and Canada as it starts the rolling review process in these jurisdictions.
South Africa is halting the use of the Oxford University-AstraZeneca COVID-19 vaccine in its vaccination campaign following the release of trial data showing the jab offered limited protection against mild to moderate infection caused by the country’s...
A single-dose intranasal influenza vaccine is safe and produces a durable immune response, according to a Phase 1 study published in the Journal of Clinical Investigation this week.
Illumina, a DNA sequencing and array-based technology specialist, is supporting the Belgian Society of Medical Oncology (BSMO) in a pilot study examining the use of comprehensive genomic profiling (CGP) in 864 patients with advanced metastatic cancer....
An Oxford University trial, a world first, is looking at whether inoculating volunteers with doses of different combinations of two currently approved COVID-19 vaccines is effective.
UK based pharma group, GlaxoSmithKline, and German biotech, CureVac, have struck a €150m (US$180m) deal to jointly develop next generation mRNA vaccines for COVID-19; the goal is to address multi-variants with one vaccine.
Pfizer and BioNTech now plan to manufacture two billion doses of their mRNA COVID-19 vaccine in 2021: up from the previous goal of 1.3 billion doses. Pfizer is forecasting $15bn in sales from the vaccine this year.
Rows about vaccine supply and threats of export blocks don’t do anything to bring us closer to ending the COVID-19 pandemic, say campaigners pushing for vaccine equity on a global level.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced they will perform an accelerated assessment of the Marketing Authorization Application (MAA) for Janssen’s investigational CAR-T therapy, ciltacabtagene...
The pharma giant had announced last week that it could deliver only 25% of the doses originally promised to the EU-27 for Q1 2021 due to production issues at one of its European factories. But it has now agreed to send 9m additional doses and will start...